William Blair Investment Management LLC Increases Stock Position in Alignment Healthcare, Inc. $ALHC

William Blair Investment Management LLC raised its position in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 43.4% during the third quarter, Holdings Channel reports. The firm owned 2,119,952 shares of the company’s stock after buying an additional 641,381 shares during the quarter. William Blair Investment Management LLC’s holdings in Alignment Healthcare were worth $36,993,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Invesco Ltd. raised its holdings in shares of Alignment Healthcare by 122.3% in the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock valued at $58,387,000 after buying an additional 2,294,739 shares during the period. Marshall Wace LLP lifted its position in shares of Alignment Healthcare by 173.3% during the second quarter. Marshall Wace LLP now owns 2,039,714 shares of the company’s stock worth $28,556,000 after purchasing an additional 1,293,416 shares in the last quarter. Voya Investment Management LLC boosted its stake in shares of Alignment Healthcare by 61.0% in the third quarter. Voya Investment Management LLC now owns 3,196,297 shares of the company’s stock valued at $55,775,000 after purchasing an additional 1,210,930 shares during the period. Qube Research & Technologies Ltd grew its holdings in shares of Alignment Healthcare by 269.6% in the second quarter. Qube Research & Technologies Ltd now owns 1,523,986 shares of the company’s stock valued at $21,336,000 after purchasing an additional 1,111,685 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in Alignment Healthcare during the 2nd quarter worth approximately $10,483,000. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. UBS Group boosted their target price on Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 14th. Robert W. Baird set a $28.00 price target on Alignment Healthcare in a report on Friday, January 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, January 21st. Finally, The Goldman Sachs Group restated a “buy” rating and set a $22.00 target price on shares of Alignment Healthcare in a research note on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alignment Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $23.95.

Insider Activity at Alignment Healthcare

In other news, President Dawn Christine Maroney sold 30,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $20.63, for a total value of $618,900.00. Following the completion of the transaction, the president owned 997,015 shares in the company, valued at $20,568,419.45. This trade represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andreas P. Wagner sold 22,238 shares of Alignment Healthcare stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $20.47, for a total value of $455,211.86. Following the transaction, the insider directly owned 169,805 shares of the company’s stock, valued at $3,475,908.35. This trade represents a 11.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 2,125,938 shares of company stock worth $41,799,570. 6.60% of the stock is currently owned by insiders.

Alignment Healthcare Price Performance

Alignment Healthcare stock opened at $19.22 on Monday. The stock has a market capitalization of $3.85 billion, a PE ratio of -1,920.08, a price-to-earnings-growth ratio of 4.90 and a beta of 1.19. The company has a debt-to-equity ratio of 1.99, a current ratio of 1.61 and a quick ratio of 1.61. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87. The business has a 50 day simple moving average of $20.99 and a 200-day simple moving average of $18.57.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.53%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the business posted ($0.16) earnings per share. The business’s revenue was up 44.4% compared to the same quarter last year. Equities analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.